AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Generalized Anxiety Disorder Adjunct Study

Phase 3

Completed

Conditions: Anxiety Neuroses
Anxiety States
Anxiety
Anxiety Disorders

Interventions: Drug: Placebo
Drug: quetiapine fumarate XR

First Posted Date: 2007-09-26

Last Posted Date: 2011-04-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 409

Registration Number: NCT00534599

Locations: 🇺🇸
Research Site, Spokane, Washington, United States

Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect

Completed

Conditions: Mania
Schizophrenia

First Posted Date: 2007-09-24

Last Posted Date: 2011-12-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 387

Registration Number: NCT00534222

Locations: 🇳🇱
Research Site, Amsterdam, Netherlands

A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel® (Quetiapine)

Completed

Conditions: Bipolar Disorder
Schizophrenia

First Posted Date: 2007-09-21

Last Posted Date: 2010-12-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 128

Registration Number: NCT00533260

Locations: 🇳🇱
Research Site, Wolfheze, Netherlands

A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®

Completed

Conditions: Asthma

First Posted Date: 2007-09-21

Last Posted Date: 2009-06-09

Lead Sponsor: AstraZeneca

Target Recruit Count: 310

Registration Number: NCT00532922

Locations: 🇨🇳
Research Site, Shanghai, China

Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)

Phase 1

Completed

Conditions: Acute Myeloid Leukaemia

First Posted Date: 2007-09-17

Last Posted Date: 2009-09-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 30

Registration Number: NCT00530699

Locations: 🇯🇵
Research Site, Fukuoka, Japan

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Dapagliflozin
Drug: Placebo
Drug: Metformin

First Posted Date: 2007-09-12

Last Posted Date: 2015-10-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 915

Registration Number: NCT00528879

Locations: 🇺🇸
Clinical Research Advantage / Desert Clinical Res, Llc, Tempe, Arizona, United States
🇺🇸
Raikhel, Marina, Torrance, California, United States
🇺🇸
Office Of Dr. Gray, Spokane, Washington, United States

and more 26 locations

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Dapagliflozin
Drug: Dapagliflozin placebo
Drug: Metformin

First Posted Date: 2007-09-12

Last Posted Date: 2015-10-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 1067

Registration Number: NCT00528372

Locations: 🇺🇸
Banksville Medical, Pc, Pittsburgh, Pennsylvania, United States
🇺🇸
Ritchken & First M.D.'S, San Diego, California, United States
🇺🇸
Village Family Practice, Houston, Texas, United States

and more 36 locations

A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

Phase 2

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Clopidogrel (over encapsulated) capsule
Drug: Ticagrelor Tablets
Drug: Aspirin Tablets

First Posted Date: 2007-09-12

Last Posted Date: 2012-01-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 123

Registration Number: NCT00528411

Locations: 🇬🇧
Research Site, Sheffield, United Kingdom

Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: AZD3480

First Posted Date: 2007-09-12

Last Posted Date: 2008-11-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 400

Registration Number: NCT00528905

Locations: 🇨🇦
Research Site, Montreal, Quebec, Canada

Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension )

Completed

Conditions: Dyslipidemia
Hypertension

First Posted Date: 2007-09-10

Last Posted Date: 2010-12-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 5000

Registration Number: NCT00526708

Locations: 🇰🇷
Research Site, Seoul, Songpa-gu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy